Nuvation Bio (NUVB) Operating Leases (2021 - 2026)

Nuvation Bio (NUVB) has reported Operating Leases for 6 consecutive years, with $2.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Leases fell 42.72% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (down 42.72% YoY), while the FY2025 annual figure was $2.5 million, up 162.44% from the prior year.
• Operating Leases retreated to $2.2 million in Q1 2026 per NUVB's latest filing, from $2.5 million in the prior quarter.
• Across five years, Operating Leases topped out at $3.8 million in Q1 2025 and bottomed at $969000.0 in Q4 2024.
• Historically, Operating Leases has averaged $2.4 million across 5 years, with a median of $2.5 million in 2025.
• Annual changes were most pronounced in 2024 — Operating Leases slumped 61.36% — and 2025, when it jumped 249.69%.
• Nuvation Bio's Operating Leases stood at $3.1 million in 2022, then plunged by 33.37% to $2.0 million in 2023, then plunged by 52.38% to $969000.0 in 2024, then soared by 162.44% to $2.5 million in 2025, then slipped by 13.53% to $2.2 million in 2026.
• Business Quant data shows NUVB's Operating Leases at $2.2 million in Q1 2026, $2.5 million in Q4 2025, and $3.0 million in Q3 2025.